CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors announced data was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal. “We continue recruiting for our Phase 2 clinical trial of KVD900,” said Andrew Crockett, Chief Executive Officer of KalVista. “In th